J&J and Genmab tout first-line injectable Darzalex for multiple myeloma: #ASH23

SAN DIEGO — J&J and Gen­mab fleshed out their case Tues­day morn­ing to move their sub­cu­ta­neous ver­sion of the can­cer drug Darza­lex in­to ear­li­er lines of treat­ment.

The da­ta for Darza­lex Faspro, the brand name for sub­cu­ta­neous Darza­lex, came from the Phase III PERSEUS tri­al that en­rolled 709 pa­tients. Those tak­ing the drug plus a stan­dard chemo reg­i­men were 58% less like­ly to see their can­cers progress com­pared to the chemo reg­i­men on its own. Physi­cians ad­min­is­tered Darza­lex Faspro in both an in­duc­tion phase and a main­te­nance phase.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.